NCT05742607Phase 2Recruiting

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-06Estimated

Enrollment · participants70Estimated

Source updated2026-06-17Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-06-17 · 1 field changed

Primary completion date changed

− Before

~~Jun 2025~~

+ After

Jun 2027

Check registry source

Study details

Conditions studied

Non Small Cell Lung Cancer

Treatments or interventions studied

IPH5201 + durvalumab + standard chemotherapyDrugAlso known as Durvalumab, MEDI4736, IMFINZI, Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy, Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy, Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy

Primary outcomes · main study measures

Read the study measures

measure: Pathological Complete Response (pCR); description: Number of patients with pathological Complete Response (pCR); timeFrame: 16 weeks after the first dose of study intervention.; measure: Adverse events (AEs) and serious adverse events (SAEs); description: Number of patients with adverse events (AEs) and serious adverse events (SAEs).; timeFrame: Until Day 90 after the last dose of study interventions.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history